. The company’s pipeline involves 4 medical-stage therapies. Its most State-of-the-art drug prospect is ROS1 inhibitor taletrectinib for managing lung most cancers. Nuvation is finishing two stage 2 pivotal scientific studies on taletrectinib. You’ll listen to me say it one millio